Immunologically Inert Nanostructures as Selective Therapeutic Tools in Inflammatory Diseases

The current therapies based on immunosuppressant or new biologic drugs often show some limitations in term of efficacy and applicability, mainly because of their inadequate targeting and of unwanted adverse reactions they generate. To overcome these inherent problems, in the last decades, innovative...

Full description

Bibliographic Details
Main Authors: Laura Talamini, Eiji Matsuura, Luisa De Cola, Sylviane Muller
Format: Article
Language:English
Published: MDPI AG 2021-03-01
Series:Cells
Subjects:
Online Access:https://www.mdpi.com/2073-4409/10/3/707
id doaj-973be7164eb546648b84626dc7864c36
record_format Article
spelling doaj-973be7164eb546648b84626dc7864c362021-03-24T00:00:40ZengMDPI AGCells2073-44092021-03-011070770710.3390/cells10030707Immunologically Inert Nanostructures as Selective Therapeutic Tools in Inflammatory DiseasesLaura Talamini0Eiji Matsuura1Luisa De Cola2Sylviane Muller3CNRS-University of Strasbourg, Biotechnology and Cell Signaling, Illkirch, France/Strasbourg Drug Discovery and Development Institute (IMS), Institut de Science et D’Ingénierie Supramoléculaire, 67000 Strasbourg, FranceNeutron Therapy Research Center, Collaborative Research Center, Department of Cell Chemistry, Okayama University, Okayama 700-8558, JapanDepartment of Molecular Biochemistry and Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milan, ItalyCNRS-University of Strasbourg, Biotechnology and Cell Signaling, Illkirch, France/Strasbourg Drug Discovery and Development Institute (IMS), Institut de Science et D’Ingénierie Supramoléculaire, 67000 Strasbourg, FranceThe current therapies based on immunosuppressant or new biologic drugs often show some limitations in term of efficacy and applicability, mainly because of their inadequate targeting and of unwanted adverse reactions they generate. To overcome these inherent problems, in the last decades, innovative nanocarriers have been developed to encapsulate active molecules and offer novel promising strategies to efficiently modulate the immune system. This review provides an overview of how it is possible, exploiting the favorable features of nanocarriers, especially with regard to their immunogenicity, to improve the bioavailability of novel drugs that selectively target immune cells in the context of autoimmune disorders and inflammatory diseases. A focus is made on nanoparticles that selectively target neutrophils in inflammatory pathologies.https://www.mdpi.com/2073-4409/10/3/707therapeutic carriersnanoparticlesdrug targetingimmunomodulationneutrophilsNETosis
collection DOAJ
language English
format Article
sources DOAJ
author Laura Talamini
Eiji Matsuura
Luisa De Cola
Sylviane Muller
spellingShingle Laura Talamini
Eiji Matsuura
Luisa De Cola
Sylviane Muller
Immunologically Inert Nanostructures as Selective Therapeutic Tools in Inflammatory Diseases
Cells
therapeutic carriers
nanoparticles
drug targeting
immunomodulation
neutrophils
NETosis
author_facet Laura Talamini
Eiji Matsuura
Luisa De Cola
Sylviane Muller
author_sort Laura Talamini
title Immunologically Inert Nanostructures as Selective Therapeutic Tools in Inflammatory Diseases
title_short Immunologically Inert Nanostructures as Selective Therapeutic Tools in Inflammatory Diseases
title_full Immunologically Inert Nanostructures as Selective Therapeutic Tools in Inflammatory Diseases
title_fullStr Immunologically Inert Nanostructures as Selective Therapeutic Tools in Inflammatory Diseases
title_full_unstemmed Immunologically Inert Nanostructures as Selective Therapeutic Tools in Inflammatory Diseases
title_sort immunologically inert nanostructures as selective therapeutic tools in inflammatory diseases
publisher MDPI AG
series Cells
issn 2073-4409
publishDate 2021-03-01
description The current therapies based on immunosuppressant or new biologic drugs often show some limitations in term of efficacy and applicability, mainly because of their inadequate targeting and of unwanted adverse reactions they generate. To overcome these inherent problems, in the last decades, innovative nanocarriers have been developed to encapsulate active molecules and offer novel promising strategies to efficiently modulate the immune system. This review provides an overview of how it is possible, exploiting the favorable features of nanocarriers, especially with regard to their immunogenicity, to improve the bioavailability of novel drugs that selectively target immune cells in the context of autoimmune disorders and inflammatory diseases. A focus is made on nanoparticles that selectively target neutrophils in inflammatory pathologies.
topic therapeutic carriers
nanoparticles
drug targeting
immunomodulation
neutrophils
NETosis
url https://www.mdpi.com/2073-4409/10/3/707
work_keys_str_mv AT lauratalamini immunologicallyinertnanostructuresasselectivetherapeutictoolsininflammatorydiseases
AT eijimatsuura immunologicallyinertnanostructuresasselectivetherapeutictoolsininflammatorydiseases
AT luisadecola immunologicallyinertnanostructuresasselectivetherapeutictoolsininflammatorydiseases
AT sylvianemuller immunologicallyinertnanostructuresasselectivetherapeutictoolsininflammatorydiseases
_version_ 1724205511586349056